Free Trial
TSE:APS

Aptose Biosciences (APS) Stock Price, News & Analysis

Aptose Biosciences logo
C$4.81 -0.62 (-11.42%)
As of 03/28/2025 03:56 PM Eastern

About Aptose Biosciences Stock (TSE:APS)

Key Stats

Today's Range
C$4.61
C$4.94
50-Day Range
C$3.81
C$9.45
52-Week Range
C$3.57
C$69.90
Volume
4,171 shs
Average Volume
2,161 shs
Market Capitalization
C$207.11 million
P/E Ratio
N/A
Dividend Yield
0.39%
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Remove Ads
Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Stock News Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Aptose and NCI Collaborate on Cancer Drug Trials
Aptose Biosciences Boosts Capital with $8M Offering
See More Headlines

APS Stock Analysis - Frequently Asked Questions

Aptose Biosciences' stock was trading at C$9.75 at the start of the year. Since then, APS shares have decreased by 50.7% and is now trading at C$4.81.
View the best growth stocks for 2025 here
.

Aptose Biosciences shares reverse split on Wednesday, February 26th 2025. The 1-30 reverse split was announced on Wednesday, February 26th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Vistagen Therapeutics (VTGN), BlackBerry (BB) and Micron Technology (MU).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:APS
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-154,685,403.90
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$3.01 per share
Price / Cash Flow
1.60
Book Value
C($0.92) per share
Price / Book
-5.25

Miscellaneous

Free Float
N/A
Market Cap
C$207.11 million
Optionable
Not Optionable
Beta
1.36
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (TSE:APS) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners